Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718143 · ClinicalTrials.gov registry record · Phase 2
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03718143 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT03718143, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed with AML receiving the combination of the drugs; Arm B has subjects who are have relapsed/refractory AML and HMA failure MDS patients being allocated to either the combination Arm B or single agent AZD1775 Arm C.
Interventions
- DRUG Combination AZD1775 with AraC
- DRUG AZD1775 only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03718143
The ClinicalTrials.gov registry entry for NCT03718143 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Combination AZD1775 with AraC is the first listed.
NCT03718143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03718143 about?
NCT03718143 is a clinical study titled "AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis". A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed with AML receiving the combination of the drugs; Arm B has subjects who are have relapsed/refractory AML and HMA fai...
What is the current status of trial NCT03718143?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-05-08. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03718143?
The interventions under investigation include: Combination AZD1775 with AraC (DRUG), AZD1775 only (DRUG).
Who is sponsoring clinical trial NCT03718143?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.